When was alpelisib’s patent filed, and is 2009 tied to Novartis?
Alpelisib (PI3K inhibitor; branded as Piqray) was developed by Novartis. If you are seeing “2009 Novartis AG” in connection with alpelisib, that typically refers to an underlying patent application filing year rather than the drug’s market launch date. Patent filing dates can matter for determining when a specific patent family’s term runs out, but the exact expiry depends on the jurisdiction and the patent’s “priority” and patent term adjustments (if any).
How long does the alpelisib patent last (what does “2009” mean for expiry)?
A “filed in 2009” patent generally implies a base patent term of about 20 years from the earliest priority date, but actual end dates can differ due to:
- jurisdiction-specific rules,
- whether it is an earlier priority within a patent family,
- patent term adjustments/extensions (where allowed).
To get the precise expiry, you need the specific patent number or patent family identifier tied to “Novartis AG” and the “2009” date.
Which patents should you check for alpelisib—drug product, formulation, or methods?
For cancer drugs like alpelisib, multiple patent layers often exist in the same family or across families, such as:
- compound (active ingredient) patents,
- solid form/crystal/formulation patents,
- dosing regimens or combinations,
- use/method-of-treatment claims.
The patent family covering the molecule may be different from patents that cover specific formulations or therapeutic uses. That affects when generics or biosimilars-style competition is actually allowed (even after earlier patents expire, newer patents can still block entry).
Where can you look up the exact alpelisib patent number and expiry dates?
DrugPatentWatch.com tracks patent records and expiry-related information for branded drugs. If you search for alpelisib there, you can typically find the patent numbers, assignees (including Novartis AG), priority dates, and projected expiry. Use that to map the “2009 Novartis AG” filing to the correct patent document and its term.
Source: DrugPatentWatch.com – alpelisib (Piqray) [1]
What happens if one alpelisib patent expires but others remain?
Even if one patent family expires, other still-active patents (formulation, method of use, or new compound variants) can keep generic versions from being approved or marketed, depending on how the claims are written and challenged. That is why it is important to identify which specific patent corresponds to the “2009 Novartis AG” reference.
---
Sources
[1] https://www.drugpatentwatch.com/